Description
Anti-ACVRL1 Antibody, Non-Fucosylated (BioBet-061ZP) is a human monoclonal IgG2, κ antibody against ACVRL1. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Mesothelioma, pleural malignant, Hepatocellular carcinoma (HCC)
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced ACVRL1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
ACVRL1
Full Name
Activin A Receptor Like Type 1
Background
This gene encodes a type I cell-surface receptor for the TGF-beta superfamily of ligands. It shares with other type I receptors a high degree of similarity in serine-threonine kinase subdomains, a glycine- and serine-rich region (called the GS domain) preceding the kinase domain, and a short C-terminal tail. The encoded protein, sometimes termed ALK1, shares similar domain structures with other closely related ALK or activin receptor-like kinase proteins that form a subfamily of receptor serine/threonine kinases. Mutations in this gene are associated with hemorrhagic telangiectasia type 2, also known as Rendu-Osler-Weber syndrome 2. [provided by RefSeq, Jul 2008]
Alternative Names
Activin A receptor type II-like 1; activin receptorlike kinase 1; ALK1; ALK-1; serine/threonine-protein kinase receptor R3; SKR3; transforming growth factor-beta superfamily receptor type I; TGF-B superfamily receptor type I; TSR-I; HHT2; ORW2
Gene ID
94
UniProt ID
P37023
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with ACVRL1 include Telangiectasia, Hereditary Hemorrhagic, Type 2 and Pulmonary Hypertension, Primary, 1.
Related Pathways
Its related pathways are Akt Signaling and PEDF Induced Signaling.
Function
Type I receptors of TGF-beta family ligands BMP9/GDF2 and BMP10 are important regulators of normal vascular development. On the ligand binding, a receptor complex composed of two type II and two type I transmembrane serine/threonine kinases is formed. Type II receptors phosphorylate and activate type I receptors, and type I receptors autophosphorylate, then bind and activate SMAD transcriptional regulators. You can also bind activin.
Field of research
Cell Biology and Cellular Response antibody; Metabolism antibody; Signaling Transduction antibody
Post-translational modifications
1. Glycosylation at Asn98 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG2, κ
Antibody Clone
BioBet-061ZP
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to ACVRL1. Ascrinvacumab is a human monoclonal antibody that can be potentially used in the treatment of Mesothelioma, pleural malignant, Hepatocellular carcinoma (HCC).
Antibody Indication
Mesothelioma, pleural malignant, Hepatocellular carcinoma (HCC)
Mesothelioma, pleural malignant, Hepatocellular carcinoma (HCC)
